Breast cancer: what's new in the NCCN guidelines?

  • Telli ML & al.
  • J Natl Compr Canc Netw
  • 1 May 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A review article highlights at least 4 major evidence-based updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Breast Cancer (BCa), including foregoing chemotherapy for patients with moderate 21-gene recurrence scores and ovarian suppression for premenopausal patients.

Why this matters

  • New additions specify diagnostic and treatment options.

Key points

  • 21-gene recurrence scores:
    • The 21-gene assay is preferred over other genetic assays because it predicts who benefits from chemotherapy.
    • The TAILORx trial showed that patients with hormone receptor (HR)-positive/node-negative disease and intermediate 21-gene scores (11-25) can forego chemotherapy, relying on endocrine therapy alone.
  • Premenopausal BCa:
    • 8-year updates to the SOFT and TEXT trials indicate that ovarian suppression (using triptorelin, oophorectomy, or ovarian irradiation) should be added to tamoxifen or exemestane for HR+/human epidermal growth factor receptor 2 (HER2)-negative early BCa (eBCa).
  • Managing the axilla in eBCa:
    • Patients with no palpable nodes, 1 or 2 positive sentinel nodes who are getting breast conservation surgery with whole-breast irradiation can avoid full axillary lymph node dissection, according to the ACOSOG Z0011 clinical trial.
  • Metastatic or advanced BCa:
    • Add CDK4/6 inhibitors to aromatase inhibitors in HR+/HER2− patients.
    • Consider new drugs like talazoparib for patients with BRCA1/2 mutations and the new immunotherapy agent atezolizumab for triple-negative breast cancer expressing PD-L1.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit